Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations
Abstract Multiple sclerosis (MS), an autoimmune central nervous system disease responsible for significant morbidity and mortality worldwide, remains imperfectly understood and treated clinically. Recent advances in treating MS have come in the form of new immunomodulatory agents. Of these, anti-CD20 monoclonal antibodies (mAbs) have exhibited particular promise in treating relapsing–remitting multiple sclerosis (RRMS), the early stage of the disease where the adaptive immune system facilitates an autoimmune attack against myelin. The depletion of CD20 positive B cells in patients with RRMS has been associated with decreased symptoms, disease progression, and lesions on MRI, as well as a more favorable side effect profile relative to other immunomodulatory therapies for MS. Of the anti-CD20 mAbs available for use in MS, one of the newest is ofatumumab, a fully human anti-CD20 IgG1κ, sold under the trade name Kesimpta. The present investigation reviews the efficacy and safety of ofatumumab for MS, highlighting the role that B cells play in the initial inflammatory stage of MS and their depletion in decreasing clinical symptoms, T2-enhancing MRI lesions, and progression to the immune-independent phase of MS..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 6(2024), 1 vom: 08. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barham, William T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Antibody-dependent cytotoxicity |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s42399-024-01649-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054701740 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054701740 | ||
| 003 | DE-627 | ||
| 005 | 20240209064705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-024-01649-7 |2 doi | |
| 035 | |a (DE-627)SPR054701740 | ||
| 035 | |a (SPR)s42399-024-01649-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barham, William T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Multiple sclerosis (MS), an autoimmune central nervous system disease responsible for significant morbidity and mortality worldwide, remains imperfectly understood and treated clinically. Recent advances in treating MS have come in the form of new immunomodulatory agents. Of these, anti-CD20 monoclonal antibodies (mAbs) have exhibited particular promise in treating relapsing–remitting multiple sclerosis (RRMS), the early stage of the disease where the adaptive immune system facilitates an autoimmune attack against myelin. The depletion of CD20 positive B cells in patients with RRMS has been associated with decreased symptoms, disease progression, and lesions on MRI, as well as a more favorable side effect profile relative to other immunomodulatory therapies for MS. Of the anti-CD20 mAbs available for use in MS, one of the newest is ofatumumab, a fully human anti-CD20 IgG1κ, sold under the trade name Kesimpta. The present investigation reviews the efficacy and safety of ofatumumab for MS, highlighting the role that B cells play in the initial inflammatory stage of MS and their depletion in decreasing clinical symptoms, T2-enhancing MRI lesions, and progression to the immune-independent phase of MS. | ||
| 650 | 4 | |a Multiple sclerosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monoclonal antibody |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CD20 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Autoimmunity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a B cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurodegeneration |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antibody-dependent cytotoxicity |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Dillman, Kathryn M. |4 aut | |
| 700 | 1 | |a Hebert, Joseph D. |4 aut | |
| 700 | 1 | |a Kerut, Christian K. |4 aut | |
| 700 | 1 | |a Klapper, Rachel J. |4 aut | |
| 700 | 1 | |a Ahmadzadeh, Shahab |4 aut | |
| 700 | 1 | |a Shekoohi, Sahar |0 (orcid)0009-0007-4545-4523 |4 aut | |
| 700 | 1 | |a Cornett, Elyse M. |4 aut | |
| 700 | 1 | |a Kaye, Alan D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 6(2024), 1 vom: 08. Feb. |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2024 |g number:1 |g day:08 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-024-01649-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2024 |e 1 |b 08 |c 02 | ||